---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-114136"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:29:09.251101+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics Q3 net loss $31.2M; cash $244.7M, expands CNTY-101 autoimmune trial, 83% ORR in lymphoma

## Summary
- Net loss $31.2M in Q3 2024; cash $244.7M; expects cash to support operations into H2 2026.
- Expanded CNTY-101 autoimmune trial to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy; basket protocol.
- ELiPSE-1 interim: 83% ORR, 33% CRR at DL3B; no DLTs or high-grade CRS/ICANS; DL4B dosing initiated.
- Strategic pipeline review to conclude Q1 2025; organizational restructuring extended cash runway.
- Appointed Morgan Conn CFO and Chad Cowan CSO; Hy Levitsky transitioned to advisor.

## SEC filing metadata
- accession: 0001104659-24-114136
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465924114136/0001104659-24-114136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465924114136/tm2427432d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-114136
- JSON: https://secwatch.observer/filing/0001104659-24-114136.json
- Plain text: https://secwatch.observer/filing/0001104659-24-114136.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.